Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Repare Therapeutics Inc. - Common Shares
(NQ:
RPTX
)
2.650
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Repare Therapeutics Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
July 15, 2025
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
May 13, 2025
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
May 01, 2025
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
April 25, 2025
From
Repare Therapeutics Inc.
Via
Business Wire
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics
↗
April 11, 2025
On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.
Via
Benzinga
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
↗
April 04, 2025
Via
Benzinga
Cathie Wood Doubles Down: Mops Up Another $1.39 Million Worth Of Robinhood Stock Amid Trump Tariff Dip
↗
April 03, 2025
On Thursday, April 3, 2025, Cathie Wood-led Ark Invest purchased Robinhood stock worth $1.39 million amid a broader market slump.
Via
Benzinga
Topics
Government
Repare Therapeutics Announces Leadership Transitions
March 31, 2025
From
Repare Therapeutics Inc.
Via
Business Wire
Cathie Wood's Ark Invest Loads Up On Robinhood, Nvidia-Backed CoreWeave: Offloads Spotify, Roku
↗
March 29, 2025
Cathie Wood-led Ark Invest made substantial trades, buying Robinhood and CoreWeave shares and selling Roblox, Genius Sports, Roku, and Spotify shares.
Via
Benzinga
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
↗
March 22, 2025
Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.
Via
Benzinga
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta
↗
March 15, 2025
Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx.
Via
Benzinga
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
Repare Therapeutics Inc.
Via
Business Wire
Gap To Rally Over 69%? Here Are 10 Top Analyst Forecasts For Friday
↗
March 07, 2025
Via
Benzinga
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 03, 2025
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
January 09, 2025
From
Repare Therapeutics Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 13, 2024
Via
Benzinga
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
↗
December 13, 2024
Via
Benzinga
Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast
↗
December 13, 2024
Via
Benzinga
Why Is Repare Therapeutics Stock Trading Lower On Friday?
↗
December 13, 2024
Repare Therapeutics shares MYTHIC trial data, highlighting Lunre+Camo's tolerability and efficacy in gynecologic cancers with FDA guidance on next steps.
Via
Benzinga
US Stocks Mixed; Broadcom Shares Surge On Upbeat Earnings
↗
December 13, 2024
Via
Benzinga
US Stocks Likely To Open Higher, Investors Eye Fed Policy Meet Next Week: Broadcom, RH, Costco In Focus
↗
December 13, 2024
U.S. stock futures advanced on Friday in premarket after declining on Thursday. The futures of all four major indices were trading higher.
Via
Benzinga
Topics
Economy
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
↗
December 13, 2024
Via
Benzinga
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
December 12, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
December 10, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
November 27, 2024
Via
Benzinga
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
November 12, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
October 23, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
October 14, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today